Skip to main content
. Author manuscript; available in PMC: 2014 Sep 1.
Published in final edited form as: J Acquir Immune Defic Syndr. 2013 Sep 1;64(1):66–73. doi: 10.1097/QAI.0b013e3182a03e9b

Figure 1. A-D Survival outcomes of 36 patients with AIDS-related diffuse large B-cell lymphoma.

Figure 1

A: 2-year OS was 40.5%; median survival was 10.5 months (95% CI 6.5 –31.8). 2-year PFS was 34.0%; median PFS time of 6.1 months (95% CI 3.8 – 30.3).

B: 2-year OS was 50.0% for ECOG score < 2 and 25.4% for ≥ 2 (p = 0.02).

C: Patients that had a response to cART showed significantly improved survival compared to those not responding (53.9% versus 18.0%; p = 0.03)25.

D: 2-year OS was 72.9% for low risk, 33.5% for intermediate risk and 27.8% for high risk (p = 0.18).

Median follow up period was 6.9 months. Patient follow up at 1 year: 13 out of 18 (72.2%) at 2 years: 9 out of 17 (52.9%) and at 3 years: 3 out of 16 (18.8%)